Strides Arcolab has moved higher by 6% to Rs 639 after the company announced that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Imiquimod cream.
The company said the US market for generic Imiquimod cream is approximately $140 million, according to IMS data.
This is the first product approval from Beltapharm, the company’s USFDA approval semi solids facility in Milan, Italy, it added.
The product will be marketed directly by Strides in the US market.
The company said the US market for generic Imiquimod cream is approximately $140 million, according to IMS data.
This is the first product approval from Beltapharm, the company’s USFDA approval semi solids facility in Milan, Italy, it added.
The product will be marketed directly by Strides in the US market.
The stock opened at Rs 601 and touched a low of Rs 601 on BSE, before the announcement. A combined 510,000 shares changed hands on the counter so far on BSE and NSE.
